302 related articles for article (PubMed ID: 33080045)
1. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs.
Ofori K; Bhagat G; Rai AJ
Br J Clin Pharmacol; 2021 Feb; 87(2):284-294. PubMed ID: 33080045
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
3. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.
Carvalho AS; Baeta H; Henriques AFA; Ejtehadifar M; Tranfield EM; Sousa AL; Farinho A; Silva BC; Cabeçadas J; Gameiro P; Silva MGD; Beck HC; Matthiesen R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681663
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
Wu FT; Lu L; Xu W; Li JY
Ann Hematol; 2019 Feb; 98(2):255-269. PubMed ID: 30368587
[TBL] [Abstract][Full Text] [Related]
6. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
8. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
9. Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
Reale A; Khong T; Xu R; Chen M; Mithraprabhu S; Bingham N; Spencer A; Greening DW
Methods Mol Biol; 2021; 2261():151-191. PubMed ID: 33420989
[TBL] [Abstract][Full Text] [Related]
10. Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
Nowakowski GS; Feldman T; Rimsza LM; Westin JR; Witzig TE; Zinzani PL
Blood Cancer J; 2019 May; 9(6):48. PubMed ID: 31097684
[TBL] [Abstract][Full Text] [Related]
11. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.
Feng Y; Zhong M; Zeng S; Wang L; Liu P; Xiao X; Liu Y
Epigenomics; 2019 Jan; 11(1):35-51. PubMed ID: 30211623
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
13. The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update.
Whiteside TL
Expert Rev Mol Diagn; 2018 Dec; 18(12):1029-1040. PubMed ID: 30406709
[No Abstract] [Full Text] [Related]
14. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids?
Regazzo G; Marchesi F; Spagnuolo M; Díaz Méndez AB; Masi S; Mengarelli A; Rizzo MG
Blood Rev; 2021 May; 47():100776. PubMed ID: 33229139
[TBL] [Abstract][Full Text] [Related]
16. Advances in Multi-Omics Study of Prognostic Biomarkers of Diffuse Large B-Cell Lymphoma.
Liang XJ; Song XY; Wu JL; Liu D; Lin BY; Zhou HS; Wang L
Int J Biol Sci; 2022; 18(4):1313-1327. PubMed ID: 35280688
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
18. Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.
Shi Y; Ding W; Gu W; Shen Y; Li H; Zheng Z; Zheng X; Liu Y; Ling Y
J Leukoc Biol; 2022 Dec; 112(6):1633-1648. PubMed ID: 36040107
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.
Lopez-Santillan M; Lopez-Lopez E; Alvarez-Gonzalez P; Martinez G; Arzuaga-Mendez J; Ruiz-Diaz I; Guerra-Merino I; Gutierrez-Camino A; Martin-Guerrero I
Crit Rev Oncol Hematol; 2021 Sep; 165():103430. PubMed ID: 34339834
[TBL] [Abstract][Full Text] [Related]
20. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
